Phase 0 clinical trials: towards a more complete ethics critique

Area of Science:

• Drug Development
• Clinical Trials
• Bioethics

Background:

• The Federal Drug Administration (FDA) has authorized exploratory IND studies, or Phase 0 trials, to modernize drug development.
• Phase 0 trials differ structurally from traditional Phase I, II, and III studies.
• These novel trial structures introduce ethical considerations not adequately addressed by current ethical frameworks.

Purpose of the Study:

• To propose an ethics critique for Phase 0 studies.
• To address the deficiency in ethical analysis for early-phase clinical trials.
• To offer a novel ethical framework for evaluating Phase 0 research.

Main Methods:

• Critique based on the means-end relation, rather than solely on benefit.
• Development of an ethic of science derived from scientific practice.
• Analysis of ethical issues specific to exploratory IND studies.

Main Results:

• Traditional ethical considerations of benefit are insufficient for Phase 0 studies.
• The means-end relationship provides a more appropriate ethical lens.
• An ethic of science grounded in practice is essential for evaluating novel research methodologies.

Conclusions:

• Phase 0 studies require a distinct ethical evaluation framework.
• Ethical critiques should focus on the relationship between research methods and goals.
• Integrating an ethic of science derived from practice is crucial for responsible innovation in drug development.